Analyst Price Target is GBX 100
▲ +304.86% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Creo Medical Group in the last 3 months. The average price target is GBX 100, with a high forecast of GBX 100 and a low forecast of GBX 100. The average price target represents a 304.86% upside from the last price of GBX 24.70.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Creo Medical Group.
Creo Medical Group PLC, through its subsidiaries, engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues; and endotherapy accessories. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, United Kingdom.